Informations générales (source: ClinicalTrials.gov)

NCT05481502 En recrutement IDF
A Prospective Trial to Evaluate Immune Determinants of the Response and the Toxicity to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Interventional
  • Tumeurs
  • Tumeurs hématologiques
N/A
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
juin 2022
juillet 2027
13 août 2025
This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs. The second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and/or toxicity. And to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and/or toxicity.
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY Camille BIGENWALD En recrutement IDF 20/06/2024 10:39:57  Contacter

Critères

Tous
Inclusion Criteria:

- Patient affiliated to a social security regimen

- Tumor lesion accessible to core biopsies

- Patient who is fully informed, able to comply with the protocol and who signed the
informed consent

- Pediatric patients > than 2 years old can be included

- No restriction about the Eastern Cooperative Oncology Group (ECOG) status


- Coagulation abnormality prohibiting a biopsy (but patients can still give their
consent for blood and bone marrow samples).

- Tumor lesion not accessible to core biopsies.

- Pregnant or nursing women cannot participate in this study.